🇺🇸 FDA

Company profile · Sponsor

WINDTREE

WINDTREE THERAPEUTICS INC /DE/

WINT · NYSE biotech WARRINGTON, PA, USA
Pipeline
15
Drugs
0
Patents
4

Quick answer

WINDTREE (WINT) is a biotech company. headquartered in WARRINGTON, PA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 4 patents to this profile..

Company facts

Ticker WINT
Exchange NYSE
Company type biotech
Headquarters WARRINGTON, PA, USA
SEC CIK 0000946486

Pipeline (15)

Search pipeline →

  1. Lucinactant

    WINDTREE

    Meconium Aspiration

    phase 3 small molecule terminated

    1 trial

  2. A.1 Lucinactant

    WINDTREE

    Acute Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  3. Aerosolized lucinactant

    WINDTREE

    Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  4. Istaroxime

    WINDTREE

    Cardiogenic Shock

    phase 2 small molecule active

    2 trials

  5. Istaroxime, LActose

    WINDTREE

    Cardiogenic Shock

    phase 2 small molecule active

    1 trial

  6. Lucinactant

    WINDTREE

    Acute Hypoxemic Respiratory Failure

    phase 2 small molecule completed

    1 trial

  7. Lucinactant

    WINDTREE

    COVID-19

    phase 2 small molecule completed

    1 trial

  8. Lucinactant 175 mg/kg

    WINDTREE

    Respiratory Distress Syndrome, Newborn

    phase 2 small molecule terminated

    1 trial

  9. Lucinactant delivered via investigational delivery device

    WINDTREE

    Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  10. Lucinactant first

    WINDTREE

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  11. Lucinactant for Inhalation

    WINDTREE

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  12. Lucinactant for inhalation

    WINDTREE

    Respiratory Distress Syndrome

    phase 2 other terminated

    2 trials

  13. Placebo

    WINDTREE

    Acute Decompensated Heart Failure

    phase 2 small molecule completed

    1 trial

  14. Rostafuroxin

    WINDTREE

    Hypertension

    phase 2 small molecule completed

    1 trial

  15. TH1902

    WINDTREE

    Solid Tumor

    phase 1 small molecule active

    1 trial

Patents (4)

Search patents →

  1. US 12343350

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11583540

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11197869

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9554999

    Lyophilization of synthetic liposomal pulmonary surfactant

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is WINDTREE?

WINDTREE (WINT) is a biotech company. headquartered in WARRINGTON, PA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 4 patents to this profile..

What pipeline programs does WINDTREE sponsor?

We track 15 ClinicalTrials.gov-linked programs for WINDTREE, including Lucinactant and 14 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does WINDTREE company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.